Status:
COMPLETED
Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body
Lead Sponsor:
Bayer
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
Study to gather information about the optimal placement of Ra-223 in the order of different treatments in terms of the effect on patients and in terms of the use of healthcare services for the treatme...
Eligibility Criteria
Inclusion
- Use of at least 2 lines of life-prolonging mCRPC therapy
- The 2nd line of life-prolonging therapy was initiated between 01-Jan-2012 to 31-Dec-2017
Exclusion
- \- No formal exclusion criteria will be applied in order to capture real world use of Ra-223
Key Trial Info
Start Date :
February 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 22 2021
Estimated Enrollment :
4301 Patients enrolled
Trial Details
Trial ID
NCT04281147
Start Date
February 24 2020
End Date
June 22 2021
Last Update
June 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations
Multiple Locations, Canada